NALP3

NACHT, LRR and PYD domains-containing protein 3 (NALP3) also known by cryopyrin is a protein that in humans is encoded by the NLRP3 gene located on the long arm of chromosome 1.

NALP3 is expressed predominantly in macrophages and as a component of the inflammasome, detects products of damaged cells such as extracellular ATP and crystalline uric acid. Activated NALP3 in turn triggers an immune response. Mutations in the NLRP3 gene are associated a number of organ specific autoimmune diseases.

Nomenclature

NACHT, LRR, and PYD are respectively acronyms for:

NACHT – NAIP (neuronal apoptosis inhibitor protein), C2TA [class 2 transcription activator, of the MHC, HET-E (heterokaryon incompatibility) and TP1 (telomerase-associated protein 1)

LRR – "leucine-rich repeat" and is synonymous with NLR, for or nucleotide-binding domain, leucine-rich repeat"

PYD – "PYRIN domain," after the pyrin proteins The NLRP3 gene name abbreviates "NLR family, pyrin domain containing 3," where NLR refers to "nucleotide-binding domain, leucine-rich repeat."

This page contains text from Wikipedia, the Free Encyclopedia - https://wn.com/NALP3

Latest News for: nlrp3

Edit

Novartis to Acquire IFM Tre to Develop First-In-Class NLRP3 Antagonist Portfolio Targeting Innate Immune System

PR Newswire 01 Apr 2019

IFM Tre launched in July 2018, with a focus on developing a suite of NLRP3 antagonists for the treatment of inflammatory diseases ... NLRP3 (NOD-, LRR- and pyrin domain-containing 3) is an intracellular innate immune signaling receptor that allows immune cells to detect the presence ......

Edit

IFM Therapeutics Announces Dosing of First Subjects in Phase 1 Healthy Volunteer Study of Lead NLRP3 Antagonist, IFM-2427

PR Newswire 28 Mar 2019

IFM-2427, the lead program from IFM's subsidiary IFM Tre, is a first-in-class systemic NLRP3 (NOD-, LRR- and pyrin domain-containing 3) antagonist that can potentially block the inflammatory responses underlying a variety of serious diseases ... NLRP3 is an intracellular innate ......

Edit

Inflazome Completes €40m ($46m) Series B Financing to Develop NLRP3 Inflammasome Inhibitors to Clinical Proof-of-Concept

Pharmiweb 19 Nov 2018

Inflazome Completes €40m ($46m) Series B Financing to Develop NLRP3 Inflammasome Inhibitors to Clinical Proof-of-Concept ... Inflazome ... ....

Edit

Forbion Leads €40m Series B Financing in Inflazome to Develop NLRP3 Inflammasome Inhibitors to Clinical Proof-of-Concept

Pharmiweb 19 Nov 2018

Forbion Leads €40m Series B Financing in Inflazome to Develop NLRP3 Inflammasome Inhibitors to Clinical Proof-of-Concept ... Forbion ... ....

Edit

Chloride regulates dynamic NLRP3-dependent ASC oligomerization and inflammasome priming [Immunology and Inflammation]

PNAS 02 Oct 2018

The NLRP3 inflammasome is an important regulator of inflammation and immunity. It is a multimolecular platform formed within cells that facilitates the activation of proinflammatory caspases to drive secretion of cytokines such as interleukin-1β (IL-1β). Knowledge of the mechanisms regulating formation of the NLRP3 inflammasome is incomplete ... ....

Edit

IFM Therapeutics, LLC Presents Promising Preclinical Data for NLRP3 Inhibitors at ACS 2018

PR Newswire 20 Aug 2018

20, 2018 /PRNewswire/ -- IFM Therapeutics, LLC (IFM), a privately held biopharmaceutical company focused on developing therapies that modulate novel targets in the innate immune system, today announced data from IFM-conducted preclinical studies on NLRP3-inhibitor compounds, which help to validate the role of NLRP3 inhibition in disease treatment....

Edit

IFM Therapeutics Announces New Publication in Nature Reviews Drug Discovery Examining NLRP3 as a Target in Serious Inflammatory and Immune-Mediated Diseases

PR Newswire 30 Jul 2018

NLRP3 (NOD-, LRR- and pyrin domain-containing 3) is an intracellular innate immune signaling receptor that allows immune cells to detect the presence of pro-inflammatory foreign or endogenous molecules that signal infection, tissue damage or metabolic derangements ... NLRP3 as a Drug Target....

Edit

IFM Therapeutics, LLC Launches Subsidiary, IFM Tre, with $31 Million Series A Financing to Develop NLRP3 Antagonists for Inflammatory Diseases

PR Newswire 19 Jul 2018

IFM Tre will focus exclusively on NLRP3, while work on other programs exploring different pathways within the innate immune system will continue in other subsidiaries within the unified IFM umbrella ... We have made substantial progress in our NLRP3 portfolio and look forward to bringing our candidates forward into the clinic."....

Edit

Targeting the IL33-NLRP3 axis improves therapy for experimental cerebral malaria [Immunology and Inflammation]

PNAS 10 Jul 2018

Cerebral malaria (CM) is a serious neurological complication caused by Plasmodium falciparum infection. Currently, the only treatment for CM is the provision of antimalarial drugs; however, such treatment by itself often fails to prevent death or development of neurological sequelae. To identify potential improved treatments for CM, we performed a......

Edit

OLT1177, a {beta}-sulfonyl nitrile compound, safe in humans, inhibits the NLRP3 inflammasome and reverses the ...

PNAS 13 Feb 2018

Activation of the NLRP3 inflammasome induces maturation of IL-1β and IL-18, both validated targets for treating acute and chronic inflammatory diseases. Here, we demonstrate that OLT1177, an orally active β-sulfonyl nitrile molecule, inhibits activation of the NLRP3 inflammasome ... ....

Edit

NLRP3 mutation and cochlear autoinflammation cause syndromic and nonsyndromic hearing loss DFNA34 responsive to anakinra ...

PNAS 12 Sep 2017

The NLRP3 inflammasome is an intracellular innate immune sensor that is expressed in immune cells, including monocytes and macrophages. Activation of the NLRP3 inflammasome leads to IL-1β secretion. Gain-of-function mutations of NLRP3 result in abnormal activation of the NLRP3 ......

Edit

Correction to Supporting Information for Conos et al., Active MLKL triggers the NLRP3 inflammasome in ...

PNAS 11 Jul 2017

IMMUNOLOGY AND INFLAMMATION Correction to Supporting Information for “Active MLKL triggers the NLRP3 inflammasome in a cell-intrinsic manner,” by Stephanie A. Conos, Kaiwen W. Chen, Dominic De Nardo, Hideki Hara, Lachlan Whitehead, Gabriel Núñez, Seth L. Masters, James M. Murphy, Kate Schroder, David L. Vaux, Kate E. Lawlor, Lisa M.... ....

Edit

Activation of NLRP3 inflammasome complex potentiates venous thrombosis in response to hypoxia [Medical Sciences]

PNAS 01 May 2017

Venous thromboembolism (VTE), caused by altered hemostasis, remains the third most common cause of mortality among all cardiovascular conditions. In addition to established genetic and acquired risk factors, low-oxygen environments also predispose otherwise healthy individuals to VTE ... ....